India’s Health Ministry wants antimicrobials treated as new drugs under the New Drugs and Clinical Trials (NDCT) Rules, 2019, a change that would require every company seeking a fresh licence to make an antibiotic, antifungal or other antimicrobial to first get permission from the Central Licensing Authority. The proposal, published as draft notification G.S.R. 983(E) dated 6 November 2026 and made public on 19 November, is open for objections and suggestions for 30 days.
Key takeaways on antimicrobials as new drugs
- What changes: “antimicrobials” would be added to the definition of “new drug” under Rule 2(1)(w)(v) of the NDCT Rules.
- New sequence: manufacturers would need Central Licensing Authority (CLA) permission before applying to a State Licensing Authority (SLA) for a manufacturing licence.
- Studies expected: bioavailability, bioequivalence and stability data, which the ministry says have not always been scrutinised.
- Existing licences: officials have said licences already granted would stay valid without fresh central permission.
- Status: draft only. Comments are due within 30 days of the gazette publication.
Why the ministry is moving now
The ministry’s stated trigger is a regulatory gap. Under India’s split system, state regulators grant most manufacturing licences, and once a molecule has been on the market long enough it no longer counts as a “new drug” needing central review. The ministry says this has allowed licences for antimicrobial products to be issued without adequate checks such as bioavailability, bioequivalence and stability studies. In its words, substandard or ineffective antimicrobials “can contribute to the development and spread of antimicrobial resistance”.
The timing also matters. The draft surfaced during World AMR Awareness Week (18 to 24 November), days after the WHO’s 2026 survey showed that most countries have AMR action plans but few fund them, as we reported in our WHO antimicrobial resistance survey coverage. The ministry also cited the G20 New Delhi Leaders’ Declaration, which called for a One Health approach to AMR.
Before and after: how licensing would work
| Step | Current practice for established antimicrobials | Under draft G.S.R. 983(E) |
|---|---|---|
| Legal status | Usually not a “new drug” once the approval window lapses | Always a “new drug” via Rule 2(1)(w)(v) |
| First approval | State Licensing Authority | Central Licensing Authority permission first |
| Manufacturing licence | Issued by the state | Still issued by the state, after CLA permission |
| Technical data | BA/BE and stability not always reviewed | BA/BE and stability studies expected |
| Existing licences | Valid | Remain valid, per ministry officials |
Rule 2(1)(w)(v) is the clause that already keeps certain product classes, such as vaccines and r-DNA derived products, permanently inside the new drug net regardless of how long they have been sold. Adding antimicrobials there is a structural choice: it does not create a new licence, it routes the class through central scrutiny every time a new manufacturer wants in.
Who is affected
- Small and mid-sized formulators: Firms that have entered generic antibiotic markets through state licences would face an extra central step and study costs for new products.
- Loan licensees and contract makers: Any new licence application for an antimicrobial product would follow the central route.
- State regulators: They keep licensing power but would act on top of a CDSCO-level permission, which could reduce variation between states.
- Patients and doctors: The intended benefit is more consistent quality, so that a cheaper brand releases the same amount of drug as the reference product.
The definition as described also covers “substances applied to skin or surfaces to reduce microbes”, based on the ministry’s explanation of the term. Whether disinfectants and topical antiseptics fall within scope is a point stakeholders are likely to raise in comments, and the final text should clarify it.
Part of a wider regulatory push
The antimicrobial draft is one of several rule changes the ministry has floated this month. It follows a proposal for a separate wholesale licence for bulk drugs and APIs, covered in our bulk drug wholesale licence report, and a draft on good storage and distribution practices. Together they point to tighter central control over quality across the supply chain, from API traders to finished antibiotics.
Market context
The stakes are commercial as well as clinical. According to Acumen Research and Consulting, the global antibiotics market was worth USD 42 billion in 2021 and is forecast to reach USD 63 billion by 2030, a CAGR of 4.6%, with Asia-Pacific the fastest-growing region and penicillins holding a significant share. India is one of the largest producers and consumers of generic antibiotics, so any change in how new manufacturers enter the market will be watched closely by industry.
How to comment and what comes next
Objections and suggestions can be sent to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi, or by email to the drugs division, within 30 days of the gazette publication. After that the Centre may finalise, revise or drop the amendment. Key questions to watch are the exact scope of “antimicrobials”, any transition period for pending applications, and what data the CLA will demand for well-established molecules.
FAQ
What is G.S.R. 983(E)?
It is the draft gazette notification, dated 6 November 2026, proposing to add antimicrobials to the new drug definition in the NDCT Rules, 2019.
Will existing antibiotic licences be cancelled?
No. Ministry officials have said licences already issued remain valid and holders do not need fresh central permission.
Why does central approval help fight AMR?
Substandard antimicrobials can deliver too little drug, letting microbes survive and adapt. Central review of bioequivalence and stability data aims to keep weak products off the market.
Is the rule final?
No. It is a draft open for public comment for 30 days.
Sources: Ministry of Health and Family Welfare statement via PTI and ANI (19 November 2026). Market data: Acumen Research and Consulting, Antibiotics Market. More in Pharmaceutical. Not legal or medical advice. Last updated 20 November 2026.

[…] The project is part of a broader ICMR push to co-develop products with Indian manufacturers; see our report on the ICMR medical device development initiative. On the regulatory side, CDSCO is also tightening rules for anti-infectives, as covered in India’s draft rule treating antimicrobials as new drugs. […]